Alembic Pharmaceuticals Ltd. - Research Center
533573 APLLTD Group (A) BSE data
Add to watchlist
| Results |
Quarterly
|
| Statement | |
| More |
Quarterly results in brief
(Rs crore)
| Dec' 20 | Sep' 20 | Jun' 20 | Mar' 20 | Dec' 19 | |
|---|---|---|---|---|---|
| Sales | 1,235.77 | 1,400.01 | 1,258.43 | 1,048.56 | 1,052.36 |
| Operating profit | 371.75 | 456.15 | 423.35 | 296.26 | 321.11 |
| Interest | 2.21 | 2.33 | 6.09 | 6.97 | 6.93 |
| Gross profit | 372.25 | 456.66 | 417.42 | 420.30 | 314.47 |
| EPS (Rs) | 14.11 | 17.72 | 16.90 | 16.67 | 12.26 |
Quarterly
results in details
| Dec' 20 | Sep' 20 | Jun' 20 | Mar' 20 | Dec' 19 | |
|---|---|---|---|---|---|
| Other income | 2.71 | 2.84 | 0.16 | 131.01 | 0.29 |
| Stock adjustment | -91.43 | -63.82 | 37.85 | -78.69 | 1.81 |
| Raw material | 325.55 | 322.66 | 256.93 | 273.30 | 233.05 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 236.53 | 250.36 | 249.37 | 204.47 | 204.62 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 393.37 | 434.66 | 290.93 | 353.22 | 291.77 |
| Provisions made | - | - | - | - | - |
| Depreciation | 38.21 | 36.71 | 35.84 | 36.35 | 34.31 |
| Taxation | 56.69 | 71.65 | 62.94 | 59.65 | 48.97 |
| Net profit / loss | 277.35 | 348.30 | 318.64 | 314.30 | 231.19 |
| Extra ordinary item | - | - | - | -10.00 | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 39.31 | 39.31 | 37.70 | 37.70 | 37.70 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 30.08 | 32.58 | 33.64 | 28.25 | 30.51 |
| GPM (%) | 30.06 | 32.55 | 33.17 | 35.63 | 29.87 |
| NPM (%) | 22.39 | 24.83 | 25.32 | 26.65 | 21.96 |
Mutual Fund Selector
Find the fund that is right for you
© 2021 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis